IL270326A - - Google Patents

Info

Publication number
IL270326A
IL270326A IL27032619A IL27032619A IL270326A IL 270326 A IL270326 A IL 270326A IL 27032619 A IL27032619 A IL 27032619A IL 27032619 A IL27032619 A IL 27032619A IL 270326 A IL270326 A IL 270326A
Authority
IL
Israel
Application number
IL27032619A
Other languages
English (en)
Other versions
IL270326B (en
IL270326B2 (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2017/048748 external-priority patent/WO2018039642A1/en
Publication of IL270326A publication Critical patent/IL270326A/en
Application filed filed Critical
Publication of IL270326B publication Critical patent/IL270326B/en
Publication of IL270326B2 publication Critical patent/IL270326B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL270326A 2017-05-04 2019-10-31 Tdr with new preparations, combinations and their methods IL270326B2 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201762501696P 2017-05-04 2017-05-04
PCT/US2017/048748 WO2018039642A1 (en) 2016-08-26 2017-08-25 Compositions and methods thereof
TW106129169A TW201815387A (zh) 2016-08-26 2017-08-28 組成物及其方法
US201862634162P 2018-02-22 2018-02-22
US201862636099P 2018-02-27 2018-02-27
US201862635554P 2018-02-27 2018-02-27
US201862636171P 2018-02-28 2018-02-28
PCT/US2018/030978 WO2018204713A1 (en) 2017-05-04 2018-05-03 Targeted drug rescue with novel compositions, combinations, and methods thereof

Publications (3)

Publication Number Publication Date
IL270326A true IL270326A (pt) 2018-05-03
IL270326B IL270326B (en) 2022-10-01
IL270326B2 IL270326B2 (en) 2023-02-01

Family

ID=65431106

Family Applications (1)

Application Number Title Priority Date Filing Date
IL270326A IL270326B2 (en) 2017-05-04 2019-10-31 Tdr with new preparations, combinations and their methods

Country Status (13)

Country Link
EP (1) EP3618819A4 (pt)
JP (2) JP7514078B2 (pt)
KR (2) KR20200062078A (pt)
CN (1) CN110831584B (pt)
AU (2) AU2018261654A1 (pt)
BR (1) BR112019022902A2 (pt)
CA (2) CA3062452C (pt)
IL (1) IL270326B2 (pt)
MA (1) MA49464A (pt)
RU (1) RU2760558C9 (pt)
TW (1) TWI787260B (pt)
WO (1) WO2018204713A1 (pt)
ZA (1) ZA201908006B (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113825510A (zh) * 2019-03-18 2021-12-21 阿瓦尼尔制药股份有限公司 使用氘化右美沙芬和奎尼丁治疗精神分裂症的阴性症状的方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220018966A (ko) * 2019-06-06 2022-02-15 제이에스알 가부시끼가이샤 감방사선성 수지 조성물, 레지스트 패턴 형성 방법 및 화합물
EP4397371A2 (en) 2020-05-19 2024-07-10 Cybin IRL Limited Deuterated tryptamine derivatives and methods of use
CN116473073A (zh) * 2023-05-08 2023-07-25 广东方中高新材料有限公司 一种含镓配合物的吡唑醚菌酯增效悬浮制剂及其制备方法
CN116473077A (zh) * 2023-05-08 2023-07-25 广东方中高新材料有限公司 一种n,n配位的镓配合物抗菌剂的合成和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4241065A (en) * 1979-07-02 1980-12-23 E. I. Du Pont De Nemours And Company Fluoro analogs of hydrocodone and oxycodone useful as analgesics, narcotic antagonists or both
US4950658A (en) * 1988-12-06 1990-08-21 Board Of Trustees Of Southern Illinois Univ. Method of medical treatment of Alzheimer's disease
US5891885A (en) 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
US6207674B1 (en) 1999-12-22 2001-03-27 Richard A. Smith Dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants
US6335371B1 (en) * 2000-11-28 2002-01-01 Orion Corporation Method for inducing cognition enhancement
TWI326214B (en) * 2002-07-17 2010-06-21 Avanir Pharmaceuticals Inc Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
CA2641392A1 (en) 2006-02-03 2007-08-16 Avanir Pharmaceuticals Pharmaceutical compositions for treating depression, anxiety and neurodegenerative disorders
EP2162135A4 (en) * 2007-05-21 2012-02-22 Reviva Pharmaceuticals Inc COMPOSITIONS, SYNTHESIS AND METHOD FOR THE APPLICATION OF ATTAINED CHINOLINONE-BASED ANTIPSYCHOTICS
US8017623B2 (en) * 2008-07-03 2011-09-13 Trinity Laboratories, Inc. Dextromethorphan hydrochloride
US9737531B2 (en) * 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
US10716784B2 (en) 2013-03-07 2020-07-21 Mindlab LLC Pain medicine combination and uses thereof
AU2014232869A1 (en) 2013-03-15 2015-10-08 Patrizia Fanara Methods for monitoring the effects of an agent in sujects with motoneuron disease with dementia
US11103499B2 (en) * 2016-08-26 2021-08-31 EXCIVA (UG) (haftungsbeschränkt) Compositions and methods thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113825510A (zh) * 2019-03-18 2021-12-21 阿瓦尼尔制药股份有限公司 使用氘化右美沙芬和奎尼丁治疗精神分裂症的阴性症状的方法

Also Published As

Publication number Publication date
EP3618819A1 (en) 2020-03-11
JP2023143940A (ja) 2023-10-06
AU2018261654A1 (en) 2019-11-14
JP7514078B2 (ja) 2024-07-10
JP2020518617A (ja) 2020-06-25
TW201842902A (zh) 2018-12-16
KR20200062078A (ko) 2020-06-03
RU2019137004A3 (pt) 2021-06-04
CA3062452C (en) 2023-10-24
IL270326B (en) 2022-10-01
EP3618819A4 (en) 2021-01-20
IL270326B2 (en) 2023-02-01
RU2760558C9 (ru) 2022-02-22
ZA201908006B (en) 2021-04-28
CN110831584A (zh) 2020-02-21
CA3062452A1 (en) 2018-11-08
CA3138116A1 (en) 2018-11-08
CN110831584B (zh) 2023-03-10
MA49464A (fr) 2020-04-29
KR20210130827A (ko) 2021-11-01
RU2019137004A (ru) 2021-06-04
RU2760558C2 (ru) 2021-11-29
AU2021215274A1 (en) 2021-09-02
KR102444803B1 (ko) 2022-09-19
WO2018204713A1 (en) 2018-11-08
TWI787260B (zh) 2022-12-21
BR112019022902A2 (pt) 2020-05-19
AU2021215274B2 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
BR122021024397A2 (pt)
BR122021023687A2 (pt)
BR122021000189A2 (pt)
BR122022025811B8 (pt)
BR112019008823A2 (pt)
BR112020006084A8 (pt)
BR122021014832A2 (pt)
BR202018014992U2 (pt)
BR122022003520A2 (pt)
BR112020008820A2 (pt)
BR202017025154U2 (pt)
BR102017023327A2 (pt)
BR202017021228U2 (pt)
BR202017020981U2 (pt)
BR202017017068U2 (pt)
BR202017016984U2 (pt)
BR202017016924U2 (pt)
BR102017015495A2 (pt)
BR102017015250A2 (pt)
BR202017012548U2 (pt)
BR202017011220U2 (pt)
BR202017010814U2 (pt)
BR202017010373U2 (pt)
BR202017009870U2 (pt)
BR202017006953U2 (pt)